Verigos John, Kordias Dimitris, Papadaki Styliani, Magklara Angeliki
Institute of Molecular Biology and Biotechnology-Foundation for Research and Technology, 45110 Ioannina, Greece.
Department of Clinical Chemistry, Faculty of Medicine, University of Ioannina, 45110 Ioannina, Greece.
Biomedicines. 2021 Oct 1;9(10):1368. doi: 10.3390/biomedicines9101368.
Cancer stem cells (CSCs) have been implicated in the development of chemoresistance, tumor recurrence and metastasis in breast cancer, thus emerging as a promising target for novel therapies. To identify novel stemness regulators that could potentially be targeted in luminal ER tumors, we performed RNA-sequencing (RNA-seq) in MCF-7 adherent monolayer cells and tumorspheres enriched in breast CSCs (bCSCs). We identified 1421 differentially expressed genes (DEGs), with 923 of them being upregulated and 498 downregulated in tumorspheres. Gene ontology and pathway enrichment analyses revealed that distinct gene networks underlie the biology of the two cell systems. We selected the transient receptor potential cation channel subfamily M member 4 () gene that had not been associated with cancer stemness before for further investigation. We confirmed that was overexpressed in tumorspheres and showed that its knock-down affected the stemness properties of bCSCs in vitro. inhibition revealed potential anti-tumor effects by directly targeting the bCSC subpopulation. We suggest that plays a key role in stemness mediation, and its inhibition may represent a novel therapeutic modality against bCSCs contributing in the improvement of breast cancer treatments.
癌症干细胞(CSCs)与乳腺癌的化疗耐药性、肿瘤复发和转移的发生有关,因此成为新型疗法的一个有前景的靶点。为了鉴定可能在腔面雌激素受体(ER)肿瘤中作为潜在靶向目标的新型干性调节因子,我们对MCF-7贴壁单层细胞和富含乳腺癌症干细胞(bCSCs)的肿瘤球进行了RNA测序(RNA-seq)。我们鉴定出1421个差异表达基因(DEGs),其中923个在肿瘤球中上调,498个下调。基因本体论和通路富集分析表明,不同的基因网络构成了这两种细胞系统生物学特性的基础。我们选择了之前未与癌症干性相关联的瞬时受体电位阳离子通道亚家族M成员4()基因进行进一步研究。我们证实该基因在肿瘤球中过表达,并表明其敲低会影响体外bCSCs的干性特性。该基因的抑制通过直接靶向bCSC亚群显示出潜在的抗肿瘤作用。我们认为该基因在干性介导中起关键作用,对其抑制可能代表一种针对bCSCs的新型治疗方式,有助于改善乳腺癌治疗。